M.G. Jannuzzo

508 total citations
28 papers, 412 citations indexed

About

M.G. Jannuzzo is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, M.G. Jannuzzo has authored 28 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 9 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in M.G. Jannuzzo's work include Cancer Treatment and Pharmacology (5 papers), Estrogen and related hormone effects (5 papers) and Microtubule and mitosis dynamics (4 papers). M.G. Jannuzzo is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Estrogen and related hormone effects (5 papers) and Microtubule and mitosis dynamics (4 papers). M.G. Jannuzzo collaborates with scholars based in Italy, France and United States. M.G. Jannuzzo's co-authors include Italo Poggesi, R. Spinelli, E. Moro, Armando Santoro, Anna Petroccione, Maurizio Rocchetti, E. Di Salle, Peter Buchan, Davide Verotta and Marta Valle and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Biochemical Pharmacology.

In The Last Decade

M.G. Jannuzzo

28 papers receiving 395 citations

Peers

M.G. Jannuzzo

ONCOL

GENET

PHARM

Rusty Kelley United States

P Nguyen France

Fatima Khwaja United States

Dirk Trommeshauser Germany

Thais M. Sielecki United States

Dirk Leysen Belgium

Takayuki Okuno Japan

Matthew Plant United States

Guishan Xiao China

Susan Hubbell United States

Rusty Kelley United States

M.G. Jannuzzo

133 ×0.8

ONCOL

391 ×3.0

41 ×0.5

GENET

34 ×0.5

PHARM

59 ×0.9

Citations per year, relative to M.G. Jannuzzo M.G. Jannuzzo (= 1×) peers Rusty Kelley

Countries citing papers authored by M.G. Jannuzzo

Since Specialization

Citations

This map shows the geographic impact of M.G. Jannuzzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.G. Jannuzzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.G. Jannuzzo more than expected).

Fields of papers citing papers by M.G. Jannuzzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.G. Jannuzzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.G. Jannuzzo. The network helps show where M.G. Jannuzzo may publish in the future.

Co-authorship network of co-authors of M.G. Jannuzzo

This figure shows the co-authorship network connecting the top 25 collaborators of M.G. Jannuzzo. A scholar is included among the top collaborators of M.G. Jannuzzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.G. Jannuzzo. M.G. Jannuzzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schöffski, P., Benjamin Besse, Thomas Gauler, et al.. (2014). Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study. Annals of Oncology. 26(3). 598–607. 48 indexed citations

Gauler, Thomas, Benjamin Besse, Silvia Novello, et al.. (2013). Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC).. Journal of Clinical Oncology. 31(15_suppl). e19138–e19138. 3 indexed citations

Bleuse, Jean‐Pierre, Hielke J. Meulenbeld, Giordano Vitali, et al.. (2011). Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 29(15_suppl). 4628–4628. 2 indexed citations

Rosen, Peter J., A. W. Tolcher, R. Spinelli, et al.. (2010). Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3066–3066. 2 indexed citations

Laffranchi, B., Maja J. De Jonge, E. Bajetta, et al.. (2010). Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC).. Journal of Clinical Oncology. 28(15_suppl). e13558–e13558. 6 indexed citations

Caponigro, Francesco, Domenica Lorusso, C. Barone, et al.. (2009). Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 66(2). 389–394. 6 indexed citations

Jannuzzo, M.G., E. Di Salle, R. Spinelli, et al.. (2008). Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Research and Treatment. 113(3). 491–499. 20 indexed citations

Zanaboni, Flavia, Simona Scalone, Gabriella Ferrandina, et al.. (2008). Phase II exploratory study of brostallicin in patients with ovarian cancer resistant/refractory to platinum-based chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 16520–16520. 2 indexed citations

Caponigro, Francesco, Michela Quirino, M Schena, et al.. (2007). 715 POSTER Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors. European Journal of Cancer Supplements. 5(4). 111–112. 1 indexed citations

10.

Valle, Marta, E. Di Salle, M.G. Jannuzzo, et al.. (2005). A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. British Journal of Clinical Pharmacology. 59(3). 355–364. 39 indexed citations

11.

Poggesi, Italo, et al.. (2004). The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemotherapy and Pharmacology. 53(6). 475–481. 20 indexed citations

12.

Jannuzzo, M.G., E. Di Salle, R. Spinelli, et al.. (2004). Estrogen suppression of 8-week treatment with exemestane combined with triptorelin versus triptorelin alone in healthy premenopausal women. Journal of Clinical Oncology. 22(14_suppl). 2041–2041. 2 indexed citations

13.

Fiorentini, Francesco, et al.. (2000). Pharmacokinetics of Single‐Dose Reboxetine in Volunteers with Renal Insufficiency. The Journal of Clinical Pharmacology. 40(5). 482–487. 19 indexed citations

14.

Denolle, Thierry, Cinzia Pellizzoni, M.G. Jannuzzo, & Italo Poggesi. (1999). Hemodynamic effects of reboxetine in healthy male volunteers*. Clinical Pharmacology & Therapeutics. 66(3). 282–287. 20 indexed citations

15.

Rey, Enrique, P. Dostert, P d'Athis, et al.. (1999). Dose proportionality of reboxetine enantiomers in healthy male volunteers. Biopharmaceutics & Drug Disposition. 20(4). 177–181. 8 indexed citations

16.

Jannuzzo, M.G., et al.. (1999). Inhibition of CYP3A4 does not influence Aromasin® (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV). European Journal of Cancer. 35. S294–S294. 8 indexed citations

17.

Fiorentini, Francesco, Italo Poggesi, M.G. Jannuzzo, et al.. (1995). P-2-76 Effect of lorazepam on the pharmacokinetics of reboxetine in healthy volunteers. European Neuropsychopharmacology. 5(3). 300–300. 3 indexed citations

18.

Benedetti, M. Strolin, E. Moro, E. Frigerio, et al.. (1990). The dispositional enantioselectivity of indobufen in rat and mouse. Biochemical Pharmacology. 40(8). 1719–1723. 10 indexed citations

19.

Jannuzzo, M.G., et al.. (1989). Pharmacokinetics and tolerance of a new penem antibiotic, FCE 22101, in healthy volunteers after a single intravenous dose. European Journal of Clinical Pharmacology. 36(6). 633–635. 7 indexed citations

20.

Moro, E., et al.. (1983). High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative. Journal of Chromatography B Biomedical Sciences and Applications. 274. 281–287. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact